With over 0.47 million KalVista Pharmaceuticals Inc (KALV) shares trading Friday and a closing price of $12.96 on the day, the dollar volume was approximately $6.03 million. The shares have shown a positive half year performance of 34.44% and its price on 01/12/24 lost nearly -1.22%. Currently, there are 34.17M common shares owned by the public and among those 19.59M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for KALV have a consensus price objective of $20.80. The analysts have set the share’s price value over the next 12 months at a high of $26.00 and a low of $16.00. The average price target is 37.69% above its recent price level and an upside to the estimated low will see the stock gain 19.0% over that period. But an upside of 50.15% will see the stock hit the forecast high price target while median target price for the stock is $20.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 33 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 16 of these insider trades were purchases, accounting for 187,867 shares. Insider sales of the common stock occurred on 17 occasions, with total insider shares sold totaling 110,936 shares.
Shares of KalVista Pharmaceuticals Inc (NASDAQ: KALV) opened at $13.25, up $0.13 from a prior closing price of $13.12. However, the script later moved the day high at 13.35, down -1.22%. The company’s stock has a 5-day price change of 13.98% and 41.18% over the past three months. KALV shares are trading 5.80% year to date (YTD), with the 12-month market performance up to 90.03% higher. It has a 12-month low price of $6.26 and touched a high of $13.14 over the same period. KALV has an average intraday trading volume of 321.70K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.81%, 33.69%, and 35.21% respectively.
Institutional ownership of KalVista Pharmaceuticals Inc (NASDAQ: KALV) shares accounts for 69.08% of the company’s 34.17M shares outstanding.
It has a market capitalization of $447.90M and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$3.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.98% over the week and 6.70% over the month.
Analysts forecast that KalVista Pharmaceuticals Inc (KALV) will achieve an EPS of -$0.75 for the current quarter, -$0.66 for the next quarter and -$2.55 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.85 while analysts give the company a high EPS estimate of -$0.67. Comparatively, EPS for the current quarter was -$0.75 a year ago. Earnings per share for the fiscal year are expected to increase by 12.31%, and 12.21% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate KalVista Pharmaceuticals Inc (KALV) as a “Strong Buy” at a consensus score of 1.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the KALV, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 15, 2020, with the firm’s price target at $30.
